Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of TACE combined with apatinib for advanced hepatocellular carcinoma in Henan Province
ChiCTR1900024030Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Henan Cancer Hospital. Primary endpoint: progression-free survival. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1900024030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024030.